GlassScriptPhysician profile
Amy K Wall
NPI 1861711426
$3,745.03
in general payments reported to CMS, 2019-2025
22 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $449 · 2023: $2,099 · 2024: $222 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $1,023 · Education: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $1,022.55 |
| Education | $475.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $1,345.04 | 2023 | Vonjo |
| Janssen Biotech, INC. | $544.26 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Amgen INC. | $349.00 | 2022-2023 | Lumakras |
| Seagen INC. | $194.95 | 2021-2024 | |
| Caris Mpi, INC. | $159.77 | 2025 | Mi Cancer Seek |
| E.R. Squibb & Sons, L.L.C. | $148.70 | 2022-2025 | Reblozyl |
| Mirati Therapeutics, INC. | $127.25 | 2023 | Krazati |
| Gilead Sciences, INC. | $126.18 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $121.50 | 2022 | |
| Blueprint Medicines Corporation | $111.90 | 2022 | |
| Daiichi Sankyo INC. | $110.74 | 2024-2025 | Enhertu |
| Incyte Corporation | $99.00 | 2021 | |
| Puma Biotechnology, INC. | $82.52 | 2021 | |
| Glaxosmithkline, LLC. | $54.29 | 2022 | |
| Myriad Genetic Laboratories, INC. | $32.00 | 2024 | Bracanalysis Cdx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $22.01 | 2025 | |
| Karyopharm Therapeutics INC. | $20.76 | 2021 | |
| Geron Corporation | $20.36 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $19.78 | 2025 | Ultomiris |
| Abbvie INC. | $19.43 | 2025 | |
| Tersera Therapeutics LLC | $19.15 | 2025 | Zoladex |
| Astrazeneca Pharmaceuticals LP | $16.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.